search

Active clinical trials for "Scleroderma, Diffuse"

Results 311-320 of 491

Rituxmab Versus IL-6 in Treating ILD

Interstitial Lung DiseaseScleroderma

All SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardiogram and stress test

Completed2 enrollment criteria

Calcinosis in a Single-Center Scleroderma Population

SclerodermaCalcinosis

This is a 10 year study of scleroderma patients with calcinosis 1) to better understand how common and if there are any risk factors for having calcinosis 2) to identify common complications associated with scleroderma-related calcinosis. .

Active2 enrollment criteria

A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab

Early and Severe Systemic Sclerosis

Rituximab 1000 mg i.v. will be given on day 1 and 15, week 26 - 28, together with a corticosteroid regimen consisting of methylprednisolone 100 mg i.v. 30 minutes prior to both infusions.

Completed32 enrollment criteria

Oral Type I Collagen for Relieving Scleroderma

SclerodermaConnective Tissue Diseases

Diffuse systemic sclerosis (SSc), or scleroderma, is a connective tissue disease causing damage to skin and other organs. The purpose of this study is to determine if taking oral bovine type I collagen (CI) will improve the condition of SSc patients.

Completed16 enrollment criteria

A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With...

SclerodermaSystemic

The main objective is to assess the potential influence of continuous intake of nintedanib on the systemic exposure of ethinylestradiol and levonorgestrel when administered in combination.

Completed24 enrollment criteria

Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.

SclerodermaSystemic

Systemic sclerosis is an autoimmune disease in which the hand is responsible for 75% of the overall disability. Management is based on systemic treatments combined with kinesitherapy aimed at maintaining joint amplitudes, improving muscle strength and preventing stiffness. The aim of this study is to describe and compare the average spontaneous and attempted reduction range of motion limitations between the dominant and contralateral hand.

Completed13 enrollment criteria

Hands on - a Hand Care Guide in Systemic Sclerosis

Scleroderma

Hands are commonly affected in Systemic Sclerosis (SS). The objective of this research is to apply a home based hand care guide in patients with SS and to evaluate its response regarding hand pain, function, strength and mobility.

Completed7 enrollment criteria

Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma

Pulmonary FibrosisScleroderma1 more

Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is available. The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO Class III and IV, to a new category of patients suffering from ILD associated with SSc.

Completed13 enrollment criteria

Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis

Systemic Sclerosis

OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma). II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.

Completed4 enrollment criteria

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo...

Scleroderma

This is a two part study. The purpose of Part A is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using one dose of BMS-986020. The purpose of Part B is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using two different doses of BMS-986020.

Withdrawn9 enrollment criteria
1...313233...50

Need Help? Contact our team!


We'll reach out to this number within 24 hrs